Shares of companies that conduct drug trials on behalf of pharmaceutical companies, such as Icon (ICLR), Iqvia (IQV), and Medpace (MEDP), are ...

ICON’s June 2025 survey of more than 100 investigators and site leaders reveals persistent bottlenecks in study startup driven by contract and budget delays, slow activation timelines, and ...

Icon reported second-quarter results highlighted by revenue of $2.1 billion, representing a nearly 5% increase from the prior-year period. However, management reduced its 2024 revenue guidance by 1.2% ...

Adoption allows ICON to take full advantage of the Medidata “Data Experience,” leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts “ICON leads in risk-based ...

In today’s ACT Brief, we look at new insights on strategy-driven clinical development, fresh survey data revealing persistent ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2023 Report. This outlines how the company is ...

DUBLIN--(BUSINESS WIRE)-- ICON plc (ICLR), (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research ...